The Impact of Infection Control Policies on Hospital Acquired Infections by MDROs from 2016 to 2023

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2024 Oct 3

PMID 39359495

Authors

Yichen Wang

Yibo Zhang

Qun Wang

Wenhui Li

Dake Shi

Yumin Xu

Affiliations

Soon will be listed here.

Abstract

Purpose: Hospital-acquired infections (HAIs) caused by multidrug-resistant organisms (MDROs) pose a significant challenge to healthcare systems. The present study aimed to evaluate the impact of the infection policy to COVID-19 on the incidence of HAIs caused by MDROs.

Methods: We conducted an eight-years retrospective analysis at a hospital in Shanghai, China. Bloodstream, sputum, and urinary tract cultures of MDROs obtained 48h after admission were collected monthly from January 2016 to Dec 2023. Occupied bed days (OBDs) were used to generate monthly HAI incidences per 10,000 OBDs. The study period was divided into pre-control, in-control, and post-control cohorts, in January 2020 and January 2022. The incidence was compared using interrupted time-series regression.

Results: In total, 6763 MDRO cultures were identified, comprising 1058 bloodstream, 4581 sputum, and 1124 urine cultures derived from 4549 patients. The incidence rates of all HAIs were 8.68 per 10,000 OBDs in the pre-control cohort, 9.76 per 10,000 OBDs in the in-control cohort and 12.58 per 10,000 OBDs in the post-control cohorts, respectively. A downward trend in the incidence of HAI was observed in the post-control cohort (p<0.05).

Conclusion: This study demonstrates that while the COVID-19 pandemic poses a significant challenge to infection control within hospitals, it provides a unique opportunity to enhance infection control measures and evaluate their effectiveness. In addition, these findings highlight the need for more targeted prevention and control strategies against different pathogens in future epidemics.

References

Bologna E, Licari L, Manfredi C, Ditonno F, Cirillo L, Fusco G . Carbapenem-Resistant in Urinary Tract Infections: From Biological Insights to Emerging Therapeutic Alternatives. Medicina (Kaunas). 2024; 60(2). PMC: 10889937. DOI: 10.3390/medicina60020214. View

Park J, Park H, Na S, Seo Y, Lee J . Trends of antimicrobial susceptibilities and multidrug-resistant colonization rate in patients transferred from long-term care facilities during 2017-2022: a cross-sectional study. BMC Infect Dis. 2024; 24(1):235. PMC: 10882737. DOI: 10.1186/s12879-024-09145-y. View

Lemonnier D, Machuel M, Obin O, Outurquin G, Adjide C, Mullie C . Trends in Antibiotic-Resistant Bacteria Isolated from Screening Clinical Samples in a Tertiary Care Hospital over the 2018-2022 Period. Antibiotics (Basel). 2023; 12(8). PMC: 10451239. DOI: 10.3390/antibiotics12081314. View

Yang X, Liu X, Li W, Shi L, Zeng Y, Xia H . Epidemiological Characteristics and Antimicrobial Resistance Changes of Carbapenem-Resistant and under the COVID-19 Outbreak: An Interrupted Time Series Analysis in a Large Teaching Hospital. Antibiotics (Basel). 2023; 12(3). PMC: 10044178. DOI: 10.3390/antibiotics12030431. View

Cahill M, Jaworski M, Harcy V, Young E, Ham D, Gable P . Cluster of Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa Among Patients in an Adult Intensive Care Unit - Idaho, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023; 72(31):844-846. PMC: 10414995. DOI: 10.15585/mmwr.mm7231a2. View

Zhang Y, Wang Y, Sheng Z, Wang Q, Shi D, Xu S . Incidence Rate, Pathogens and Economic Burden of Catheter-Related Bloodstream Infection: A Single-Center, Retrospective Case-Control Study. Infect Drug Resist. 2023; 16:3551-3560. PMC: 10256568. DOI: 10.2147/IDR.S406681. View

Fasciana T, Antonelli A, Bianco G, Lombardo D, Codda G, Roscetto E . Multicenter study on the prevalence of colonization due to carbapenem-resistant strains before and during the first year of COVID-19, Italy 2018-2020. Front Public Health. 2024; 11:1270924. PMC: 10771343. DOI: 10.3389/fpubh.2023.1270924. View

Huang H, Wu K, Chen H, Wang J, Chen L, Lai Z . The impact of the COVID-19 pandemic on nosocomial infections: a retrospective analysis in a tertiary maternal and child healthcare hospital. Front Public Health. 2023; 11:1132323. PMC: 10151874. DOI: 10.3389/fpubh.2023.1132323. View

Thomsen J, Menezes G, Abdulrazzaq N, Ayoub Moubareck C, Senok A, Everett D . Evolving trends among : a 12-year retrospective study from the United Arab Emirates. Front Public Health. 2023; 11:1243973. PMC: 10721971. DOI: 10.3389/fpubh.2023.1243973. View

10.

Jernigan J, Hatfield K, Wolford H, Nelson R, Olubajo B, Reddy S . Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med. 2020; 382(14):1309-1319. PMC: 10961699. DOI: 10.1056/NEJMoa1914433. View

11.

Andrianopoulos I, Maniatopoulou T, Lagos N, Kazakos N, Papathanasiou A, Papathanakos G . Bloodstream Infections in the COVID-19 Era: A Comparative Analysis between COVID-19 and Non-COVID-19 Critically Ill Patients. Microorganisms. 2023; 11(7). PMC: 10383443. DOI: 10.3390/microorganisms11071811. View

12.

Dobrovic K, Skrobo T, Selec K, Jelic M, Civljak R, Persec J . Healthcare-Associated Bloodstream Infections Due to Multidrug-Resistant in COVID-19 Intensive Care Unit: A Single-Center Retrospective Study. Microorganisms. 2023; 11(3). PMC: 10056625. DOI: 10.3390/microorganisms11030774. View

13.

Abubakar U, Al-Anazi M, Alanazi Z, Rodriguez-Bano J . Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review. J Infect Public Health. 2023; 16(3):320-331. PMC: 9804969. DOI: 10.1016/j.jiph.2022.12.022. View

14.

Tacconelli E, Cataldo M, Dancer S, de Angelis G, Falcone M, Frank U . ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2013; 20 Suppl 1:1-55. DOI: 10.1111/1469-0691.12427. View

15.

Plachouras D, Kacelnik O, Rodriguez-Bano J, Birgand G, Borg M, Kristensen B . Revisiting the personal protective equipment components of transmission-based precautions for the prevention of COVID-19 and other respiratory virus infections in healthcare. Euro Surveill. 2023; 28(32). PMC: 10416576. DOI: 10.2807/1560-7917.ES.2023.28.32.2200718. View

16.

Farthing T, Jolley A, Nickel K, Hill C, Stwalley D, Reske K . Early coronavirus disease 2019 (COVID-19) pandemic effects on individual-level risk for healthcare-associated infections in hospitalized patients. Infect Control Hosp Epidemiol. 2023; 44(12):1966-1971. PMC: 10755158. DOI: 10.1017/ice.2023.83. View

17.

Alcantar-Curiel M, Huerta-Cedeno M, Jarillo-Quijada M, Gayosso-Vazquez C, Fernandez-Vazquez J, Hernandez-Medel M . Gram-negative ESKAPE bacteria bloodstream infections in patients during the COVID-19 pandemic. PeerJ. 2023; 11:e15007. PMC: 10066687. DOI: 10.7717/peerj.15007. View

18.

Pu D, Zhao J, Chang K, Zhuo X, Cao B . "Superbugs" with hypervirulence and carbapenem resistance in Klebsiella pneumoniae: the rise of such emerging nosocomial pathogens in China. Sci Bull (Beijing). 2023; 68(21):2658-2670. DOI: 10.1016/j.scib.2023.09.040. View

19.

Ismael Y, Pacheco E Castilho H, Zhen F, Yamaguto G, Moriya V, Maestri A . Clinical and microbiological profile of health care-associated infections in a tertiary hospital: Comparison between a cohort of hospitalized patients during prepandemic and COVID-19 pandemic periods. Am J Infect Control. 2024; 52(6):712-718. DOI: 10.1016/j.ajic.2023.12.018. View

20.

Amodio E, Pizzo S, Vella G, De Francisci V, Distefano S, Giambelluca E . Increase of multidrug-resistant bacteria after the COVID-19 pandemic in a major teaching Hospital in Sicily (2018-2021). Int J Antimicrob Agents. 2024; 63(5):107123. DOI: 10.1016/j.ijantimicag.2024.107123. View